SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

Add BTX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/22/2017 3:29:33 PM - Followers: 70 - Board type: Free - Posts Today: 0


BioTime, Inc.  (BTX)





Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389






BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us


The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:









Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at:





Recent News:








Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038


Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

Phone:  510.521.3390 ext 301






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BTX News: BioTime Presents Retinal Restoration Data at ARVO 05/11/2017 07:00:00 AM
BTX News: Current Report Filing (8-k) 05/10/2017 04:10:38 PM
BTX News: Quarterly Report (10-q) 05/10/2017 04:09:22 PM
BTX News: BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments 05/10/2017 04:01:00 PM
BTX News: BioTime Announces New Positive Data from OpRegenĀ® Trial in Dry-AMD 05/09/2017 07:00:00 AM
#646   Sub OCX great news. Revs 2nd half 17'. poonch1ne 05/22/17 03:29:33 PM
#645   Hi P, and welcome to the board, pretty Adi2 05/17/17 02:07:46 PM
#644   Hello board. I'm new to Biotime and just Perkin78 05/16/17 07:40:09 AM
#643   BTX Conf call notes 1Q2017. Adi2 05/11/17 07:14:09 AM
#642   Link: ahab333 05/09/17 09:22:27 AM
#641   Oh I intend to wait for this Adi2, ahab333 04/09/17 06:27:56 PM
#640   The Stem Cell sector is, still considered a Adi2 04/08/17 12:39:23 AM
#639   I know I am relatively new on the ahab333 04/06/17 10:40:28 AM
#638   Good morning Biotime posters. I like what ahab333 04/05/17 10:40:24 AM
#637   What positive news? Cincinnatus 04/01/17 10:35:12 AM
#636   $BTX. Nice end of day panic. Now moving BusterCWK 03/31/17 06:06:09 PM
#635   $BTX. Should run up into close and after BusterCWK 03/31/17 02:14:21 PM
#634   $BTX. I am long. $6.00 price target BusterCWK 03/31/17 01:41:06 PM
#633   To clarify: This Breakthrough In Biotech Has Enormous Investment Potential xoc 02/11/17 08:49:43 PM
#632   The article I posted "This Breakthrough ..." xoc 02/11/17 08:38:52 PM
#631   BioTime Acquires Retinal Repair Cell Therapy from UPMC xoc 02/10/17 09:12:34 PM
#630   This Breakthrough In Biotech Has Enormous Investment Potential xoc 02/10/17 09:02:28 PM
#629   Thank you kindly for posting that. Bluesummers 01/26/17 05:39:48 PM
#628   Must watch for anyone who does DD on Adi2 12/15/16 02:22:34 AM
#627   BioTime, Inc. has added a news release to Adi2 11/18/16 06:23:21 AM
#626   BTX.WS expire in October of 2018 and have Adi2 10/24/16 08:00:45 AM
#625   BTX/W: do you guys know anything about the jboatswain 10/24/16 02:03:32 AM
#624   fast and steady profit scan BTX bullish 3.90 stocktrademan 09/30/16 04:53:20 PM
#623   This is like a better version of IBB poonch1ne 09/23/16 12:12:08 PM
#621   BTX bullish 3.53 stocktrademan 09/22/16 10:18:25 AM
#620 Adi2 09/08/16 08:33:53 AM
#619   Yes, this is epic. Neuroscientists at Keck sokol 09/07/16 09:48:03 PM
#618   This sends shivers down my spine. It's the Adi2 09/07/16 01:31:45 PM
#617   Take notice: Insiders are financing this microcap an Adi2 09/02/16 01:31:47 AM
#616   Global Stem Cells Market to Reach US $119.5 H20-Life 08/22/16 01:13:02 AM
#615   I just love trading BTX around 2.3$ to Adi2 05/21/16 01:14:55 AM
#614   WARF is involved with ongoing stem cell XenaLives 04/23/16 09:05:30 AM
#613   What split LOL Stock Guy777 02/01/16 03:44:48 PM
#612   Glad I sold btx before split can now Dynarod 01/21/16 06:28:58 AM
#611   oh yay! Stock Guy777 01/05/16 11:06:05 AM
#610   BioTime's subsidiary OCX begging trading today, envirogym 12/30/15 02:51:40 PM
#609   1 for 20 is not a big deal envirogym 12/23/15 01:40:17 PM
#608   Bear in mind all that the stock will Dynarod 12/23/15 01:22:04 PM
#607   Getting some spin off shares. BioTime, Inc. has Stock Guy777 12/11/15 09:02:16 AM
#606   $BTX recent news/filings stocktrademan 12/06/15 02:22:17 PM
#605   The 2 CEOs: Mike west is now in to Adi2 12/04/15 07:14:15 AM
#604   I can only hope it's good news :-) BTX Stock Guy777 12/03/15 09:23:32 AM
#603   WEST gets a CO-CEO. Why? Is the Board getting restless? Is Adi2 12/01/15 11:28:22 PM
#602   TESAs move is against corporations that have no Adi2 11/17/15 11:43:01 PM
#601   TASE moves to limit exploitative listings by foreign DewDiligence 11/17/15 05:04:51 PM
#600   Lots of action jackson, you'al see if ya envirogym 10/19/15 05:34:21 PM
#599   Been holding for years and will continue no Stock Guy777 10/19/15 09:42:30 AM
#598   Pumping club terragord7 10/16/15 11:38:55 PM
#597   Btx Cbdpotential 10/16/15 05:09:40 AM
#596   You got that right! :-) BTX BOOM Stock Guy777 10/15/15 10:22:30 PM